-
1
-
-
79961199944
-
Hepatitis C virus infection in USA: An estimate of true prevalence
-
Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101
-
(2011)
Liver Int
, vol.31
, pp. 1090-1101
-
-
Chak, E.1
Talal, A.H.2
Sherman, K.E.3
Schiff, E.R.4
Saab, S.5
-
2
-
-
73149113990
-
Public health impact of antiviral therapy for hepatitis C in the United States
-
Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-5
-
(2009)
Hepatology
, vol.50
, pp. 1750-1755
-
-
Volk, M.L.1
Tocco, R.2
Saini, S.3
Asf, L.4
-
3
-
-
33846457516
-
Self-reported hepatitis C virus antibody status and risk behavior in young injectors
-
Hagan H, Campbell J, Thiede H., et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121: 710-9
-
(2006)
Public Health Rep
, vol.121
, pp. 710-719
-
-
Hagan, H.1
Campbell, J.2
Thiede, H.3
-
4
-
-
84901911155
-
Hepatitis C treatment triumphs
-
Rice CM, Saeed M. Hepatitis C: treatment triumphs. Nature 2014; 510: 43-4
-
(2014)
Nature
, vol.510
, pp. 43-44
-
-
Rice, C.M.1
Saeed, M.2
-
5
-
-
34047134914
-
Rate and predictors of treatment prescription for hepatitis C.
-
Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9
-
(2007)
Gut
, vol.56
, pp. 385-389
-
-
Butt, A.A.1
Justice, A.C.2
Skanderson, M.3
Rigsby, M.O.4
Good, C.B.5
Kwoh, C.K.6
-
6
-
-
43349090325
-
Limited uptake of hepatitis C treatment among injection drug users
-
Mehta SH, Genberg BL, Astemborski J., et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33
-
(2008)
J Community Health
, vol.33
, pp. 126-133
-
-
Mehta, S.H.1
Genberg, B.L.2
Astemborski, J.3
-
7
-
-
84906678391
-
Can hepatitis C be eradicated in the United States?
-
Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States?. Antiviral Res 2014; 110C: 79-93
-
(2014)
Antiviral Res
, vol.110 C
, pp. 79-93
-
-
Edlin, B.R.1
Winkelstein, E.R.2
-
8
-
-
33646852746
-
The prevalence of hepatitis C virus infection in the United States 1999 through 2002
-
Armstrong GL. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705
-
(2006)
Ann Intern Med
, Issue.144
, pp. 705
-
-
Armstrong, G.L.1
-
9
-
-
84867288022
-
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
-
Smith BD, Morgan RL, Beckett GA., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32
-
(2012)
MMWR Recomm Rep
, Issue.61
, pp. 1-32
-
-
Smith, B.D.1
Morgan, R.L.2
Beckett, G.A.3
-
10
-
-
84863393363
-
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. Primary care settings
-
Rein DB, Smith BD, Wittenborn JS., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-70
-
(2012)
Ann Intern Med
, vol.156
, pp. 263-270
-
-
Rein, D.B.1
Smith, B.D.2
Wittenborn, J.S.3
-
11
-
-
84905656313
-
The changing burden of hepatitis C virus infection in the United States: Model-based predictions
-
Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014; 161: 170-80
-
(2014)
Ann Intern Med
, vol.161
, pp. 170-180
-
-
Kabiri, M.1
Jazwinski, A.B.2
Roberts, M.S.3
Schaefer, A.J.4
Chhatwal, J.5
-
12
-
-
84880998187
-
Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy
-
Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(suppl 2): S39-45
-
(2013)
Clin Infect Dis
, vol.57 SUPPL2
, pp. S39-S45
-
-
Martin, N.K.1
Hickman, M.2
Hutchinson, S.J.3
Goldberg, D.J.4
Vickerman, P.5
-
13
-
-
84895766895
-
Editorial commentary: Hepatitis C virus testing and drug use in North America is there more than meets the eye?
-
Beckwith CG, Larney S, Flanigan TP. Editorial commentary: hepatitis C virus testing and drug use in North America; is there more than meets the eye?. Clin Infect Dis 2014; 58: 762-4
-
(2014)
Clin Infect Dis
, vol.58
, pp. 762-764
-
-
Beckwith, C.G.1
Larney, S.2
Flanigan, T.P.3
-
14
-
-
84901363195
-
Estimating the number of persons who inject drugs in the United States by meta-Analysis to calculate national rates of HIV and hepatitis C virus infections
-
Lansky A, Finlayson T, Johnson C., et al. Estimating the number of persons who inject drugs in the United States by meta-Analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014; 9: e97596
-
(2014)
PLoS One
, vol.9
, pp. e97596
-
-
Lansky, A.1
Finlayson, T.2
Johnson, C.3
-
15
-
-
84884490240
-
Model for hepatitis C virus transmission
-
Elbasha E. Model for hepatitis C virus transmission. Math Biosci Eng 2013; 10: 1045-65
-
(2013)
Math Biosci Eng
, vol.10
, pp. 1045-1065
-
-
Elbasha, E.1
-
16
-
-
0026747914
-
The declining risk of post-Transfusion hepatitis C virus infection
-
Donahue JG, Muñoz A, Ness PM., et al. The declining risk of post-Transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73
-
(1992)
N Engl J Med
, vol.327
, pp. 369-373
-
-
Donahue, J.G.1
Muñoz, A.2
Ness, P.M.3
-
17
-
-
49649118223
-
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-Analysis and meta-regression
-
Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-Analysis and meta-regression. Hepatology 2008; 48: 418-31
-
(2008)
Hepatology
, vol.48
, pp. 418-431
-
-
Thein, H.-H.1
Yi, Q.2
Dore, G.J.3
Krahn, M.D.4
-
18
-
-
84883450412
-
Treatment of hepatitis C in the patient with decompensated cirrhosis
-
Everson GT, Bhatt A. Treatment of hepatitis C in the patient with decompensated cirrhosis. Curr Hepat Rep 2013; 12: 236-45
-
(2013)
Curr Hepat Rep
, vol.12
, pp. 236-245
-
-
Everson, G.T.1
Bhatt, A.2
-
19
-
-
0033584440
-
The prevalence of hepatitis C virus infection in the United States 1988 through 1994
-
Alter MJ, Kruszon-Moran D, Nainan OV., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62
-
N Engl J Med
, vol.1999
, Issue.341
, pp. 556-562
-
-
Alter, M.J.1
Kruszon-Moran, D.2
Nainan, O.V.3
-
20
-
-
46249094710
-
Prevalence of hepatitis C virus infection among injection drug users in the United States 1994-2004
-
Amon JJ, Garfein RS, Ahdieh-Grant L., et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008; 46: 1852-8
-
(2008)
Clin Infect Dis
, Issue.46
, pp. 1852-1858
-
-
Amon, J.J.1
Garfein, R.S.2
Ahdieh-Grant, L.3
-
21
-
-
84962315109
-
Factors associated with spontaneous clearance during acute hepatitis C virus infection
-
Grebely J, Dore GJ, Van Der Loeff MS., et al. Factors associated with spontaneous clearance during acute hepatitis C virus infection. J Hepatol 2010; 52: S411
-
(2010)
J Hepatol
, vol.52
, pp. S411
-
-
Grebely, J.1
Dore, G.J.2
Van Der Loeff, M.S.3
-
22
-
-
27644489043
-
Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: A European case-control study
-
Yazdanpanah Y, De Carli G, Migueres B., et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005; 41: 1423-30
-
(2005)
Clin Infect Dis
, vol.41
, pp. 1423-1430
-
-
Yazdanpanah, Y.1
De Carli, G.2
Migueres, B.3
-
23
-
-
0031836665
-
Serum and liver HCV RNA levels in patients with chronic hepatitis C: Correlation with clinical and histological features
-
De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42: 856-60
-
(1998)
Gut
, vol.42
, pp. 856-860
-
-
De Moliner, L.1
Pontisso, P.2
De Salvo, G.L.3
Cavalletto, L.4
Chemello, L.5
Alberti, A.6
-
24
-
-
0034918152
-
Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers
-
Yeo AET, Ghany M, Conry-Cantilena C., et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 256-63
-
(2001)
J Viral Hepat
, vol.8
, pp. 256-263
-
-
Aet, Y.1
Ghany, M.2
Conry-Cantilena, C.3
-
25
-
-
20444375028
-
Dynamics of viremia in early hepatitis C virus infection
-
Glynn SA, Wright DJ, Kleinman SH., et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: 994-1002
-
(2005)
Transfusion
, vol.45
, pp. 994-1002
-
-
Glynn, S.A.1
Wright, D.J.2
Kleinman, S.H.3
-
26
-
-
0036789296
-
Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore Maryland
-
Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis 2002; 35: 783-8
-
(2002)
Clin Infect Dis
, vol.35
, pp. 783-788
-
-
Ompad, D.C.1
Fuller, C.M.2
Vlahov, D.3
Thomas, D.4
Strathdee, S.A.5
-
27
-
-
84937029422
-
A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs
-
Spelman T, Morris MD, Zang G., et al. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. J Epidemiol Community Heal 2015; 69: 745-52
-
(2015)
J Epidemiol Community Heal
, vol.69
, pp. 745-752
-
-
Spelman, T.1
Morris, M.D.2
Zang, G.3
-
28
-
-
84860297348
-
Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine
-
Grebely J, Prins M, Hellard M., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 408-14
-
(2012)
Lancet Infect Dis
, vol.12
, pp. 408-414
-
-
Grebely, J.1
Prins, M.2
Hellard, M.3
-
29
-
-
72249087933
-
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection
-
Osburn WO, Fisher BE, Dowd KA., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-24
-
(2010)
Gastroenterology
, vol.138
, pp. 315-324
-
-
Osburn, W.O.1
Fisher, B.E.2
Dowd, K.A.3
-
30
-
-
33746546870
-
Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States
-
Nainan OV, Alter MJ, Kruszon-Moran D., et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84
-
(2006)
Gastroenterology
, vol.131
, pp. 478-484
-
-
Nainan, O.V.1
Alter, M.J.2
Kruszon-Moran, D.3
-
31
-
-
84877739274
-
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
-
Jacobson IM, Gordon SC, Kowdley KV., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
-
(2013)
N Engl J Med
, vol.368
, pp. 1867-1877
-
-
Jacobson, I.M.1
Gordon, S.C.2
Kowdley, K.V.3
-
32
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
Sulkowski MS, Gardiner DF, Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
-
33
-
-
84939262043
-
Lack of health insurance limits the benefits of hepatitis C virus screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study
-
Ditah I, Al Bawardy B, Gonzalez HC., et al. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study. Am J Gastroenterol 2015; 110: 1126-33
-
(2015)
Am J Gastroenterol
, vol.110
, pp. 1126-1133
-
-
Ditah, I.1
Al Bawardy, B.2
Gonzalez, H.C.3
-
34
-
-
84923486405
-
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
-
Galbraith JW, Franco RA, Donnelly JP., et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015; 61: 776-82
-
(2015)
Hepatology
, vol.61
, pp. 776-782
-
-
Galbraith, J.W.1
Franco, R.A.2
Donnelly, J.P.3
-
35
-
-
84892397492
-
Barriers and facilitators of hepatitis C screening among people who inject drugs: A multicity, mixed-methods study
-
Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multicity, mixed-methods study. Harm Reduct J 2014; 11: 1
-
(2014)
Harm Reduct J
, vol.11
, pp. 1
-
-
Barocas, J.A.1
Brennan, M.B.2
Hull, S.J.3
Stokes, S.4
Fangman, J.J.5
Westergaard, R.P.6
-
36
-
-
84912062011
-
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
-
Abenavoli L, Masarone M, Peta V., et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20: 15233-40
-
(2014)
World J Gastroenterol
, vol.20
, pp. 15233-15240
-
-
Abenavoli, L.1
Masarone, M.2
Peta, V.3
-
37
-
-
63449089688
-
Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users
-
Hahn JA, Wylie D, Dill J., et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009; 1: 47-57
-
(2009)
Epidemics
, vol.1
, pp. 47-57
-
-
Hahn, J.A.1
Wylie, D.2
Dill, J.3
-
38
-
-
84924901173
-
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
-
Chhatwal J, Kanwal F, Roberts MS, Dunn M.A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162: 397-406
-
(2015)
Ann Intern Med
, vol.162
, pp. 397-406
-
-
Chhatwal, J.1
Kanwal, F.2
Roberts, M.S.3
Dunn, M.A.4
-
39
-
-
70449085441
-
Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
-
Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454-89
-
(2009)
Transfusion
, vol.49
, pp. 2454-2489
-
-
Kleinman, S.H.1
Lelie, N.2
Busch, M.P.3
|